Covaxin is expected to be approved by the WHO in 4-6 weeks, according to the lead scientist.

Covaxin’s Phase-3 clinical trial results were recently disclosed by Bharat Biotech. Covaxin was shown to be 77.8% effective against symptomatic Covid-19, according to the study report.

In the next four to six weeks, the World Health Organization is expected to approve Bharat Biotech’s Covaxin, India’s sole indigenously created vaccine in use so far, for an emergency use listing, according to head scientist Dr. Soumya Swaminathan.

“For approval, there is a procedure to follow. For clearance, businesses must provide their safety data, comprehensive trial data, and even manufacturing quality data. Bharat Biotech has already begun providing data, and the dossier is now being evaluated. Our group is now reviewing the next vaccination. During a webcast on vaccine availability throughout the world, Dr. Swaminathan stated, “There will be a decision on inclusion in the next four to six weeks.”

Swaminathan stated in a recent interview that the Phase 3 trial data for Covaxin “looks excellent” and so far fulfills the international public health agency’s safety profile.

Covaxin’s Phase-3 clinical trial results were recently disclosed by Bharat Biotech. Covaxin was shown to be 77.8% effective against symptomatic Covid-19, according to the study report.

Covaxin has already been approved for emergency use in 16 countries throughout the world, including Brazil, Mexico, the Philippines, and Iran.

If granted, the WHO permission will provide relief to Indians and inhabitants of at least 12 nations where the vaccine is now being delivered.

Swaminathan spoke at the event and highlighted recent meta-analysis findings on the anti-parasitic medication Ivermectin as a potential Covid-19 therapy.